Givinostat conditionally approved to treat patients with Duchenne muscular dystrophy (DMD).
In a significant development for patients with Duchenne muscular dystrophy (DMD), the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a conditional marketing authorisation for the medicine givinostat, also known as Duvyzat.
This approval, announced on 20 December 2024, marks a crucial step forward in the treatment of this debilitating genetic disorder.
Givinostat is a nonsteroidal drug indicated for the treatment of patients aged 6 years of age and older with all genetic variants of DMD. [Read more: Qu'est-ce que Duvyzat (Givinostat) ?]
